New Open-Label Data Highlights Therapeutic Potential of Bexicaserin in Developmental and Epileptic Encephalopathies

Over a 52-week treatment period, patients who continued on bexicaserin and those who switched from placebo demonstrated notable decreases in motor seizures, further supporting the agent’s development.:

Source: Neurology Read More